CompletedPhase 1NCT04920292

PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets

Studying Filariasis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Swiss Tropical & Public Health Institute
Principal Investigator: Daniel Paris
Swiss TPH
Intervention: Oxfendazole(drug)
Enrollment: 30 enrolled
Eligibility: 18-45 years · All sexes
Timeline: 2022 – 2022

Study locations (1)

Ifakara Health Institute, Bagamoyo, Tanzania

Collaborators

Ifakara Health Institute · Drugs for Neglected Diseases

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04920292 on ClinicalTrials.gov

Other trials for Filariasis

Additional recruiting or active studies for the same condition.

RECRUITINGNCT00001230
Host Response to Infection and Treatment in Filarial Diseases
National Institute of Allergy and Infectious Diseases (NIAID)

See all trials for Filariasis →

← Back to all trials